In conclusion losartan improves insulin-mediated glucose uptake through an increase in NOGM and blood Losartan vs placebo lowered systolic blood pressure by 163 ؎ 3.5 and 147 ؎ 4.1 mm Hg (P Ͻ Ͻ Ͻ 0.001), and diastolic flow in hypertensive patients.
Introduction
administration is also associated with a rise in Insulin resistance in patients with arterial hypertenplasma bradykinin concentration 7 which contribsion may be due to sympathetic nervous system utes to the hypotensive effect 8 and to the improveoverdrive 1 with a reduction in non-oxidative glument in insulin action. 9 Angiotensin II antagonists cose metabolism (NOGM) and in blood flow. [1] [2] [3] By lack the bradykinin potentiating action of ACE contrast, vasodilatation with an increase in blood inhibitors 10 thus allowing one to differentiate the flow lowers arterial blood pressure (BP) and effect due to angiotensin II blockade from that of braimproves insulin-mediated glucose uptake. 2 Several dykinin. Recently, angiotensin II antagonism has drugs have been tested to examine those combining been shown to improve insulin action. 11 Neverthethe antihypertensive effect with metabolic benefits.
less, in such studies no data on substrate oxidation Angiotensin-converting enzyme (ACE) inhibitors 1, 4, 5 and blood flow were provided. Thus, we tested the and ␣1-adrenergic antagonists 1, 6 seem to meet such hypothesis that AT 1 antagonism improves insulin criteria. Recently, the first non-peptide angiotensin action through a rise in blood flow and a change in II antagonist (losartan) has been developed and substrate oxidation in insulin-treated hypertensive made available for clinical use. Briefly, the antipatients. To assess this hypothesis, hypertensive hypertensive effect of losartan is due to the high patients were treated with losartan while changes in specificity inhibition of angiotensin II receptor (AT 1 insulin-mediated glucose uptake, substrate oxisubtype). Thus, vasodilation and BP reduction occur dation and blood flow were determined by euglycaemic hyperinsulinaemic glucose clamp, indirect calorimetry and echodoppler techniques respect-ometer when patients had been sitting for approxi-
Materials and methods
mately 1 h. The disappearance of sound (phase V) Subjects was used for diastolic reading. Mean value of the last two recorded measurements was considered Sixteen newly diagnosed patients with mild-tofor analysis. moderate hypertension volunteered for the study.
Before and along glucose clamp, blood flow was Patients were considered to be hypertensive accorddetermined in a segment of a common femoral artery ing to their clinic BP levels (diastolic BP [DBP] Ͼ90 with a circular cross-section. Measurements were mm Hg taken as a mean of three different measuremade by image-directed duplex ultrasonography ments in at least three different visits at 1-week combining B-mode imaging and pulse Doppler intervals). All patients had a normal glucose tolerbeams (Apogee CX 200, Interstice ATL, Ambler, PA, ance (75 g glucose) according to WHO criteria. 12 USA). Blood flow volumes were automatically calExclusion criteria from the study were a family hisculated as the product of the vessel cross-sectional tory of diabetes and obesity, coronary artery disease, area, and the time averaged blood velocity from congestive heart failure, valvular heart disease, seven repeated measurements. Blood flow did not impaired glucose tolerance and diabetes mellitus.
differ between each leg and pooled data are All patients were free from cardiac medication and presented accordingly. The investigator performing drugs known to interfere with glucose metabolism the duplex measurements was blinded to the treatand had a similar sedentary lifestyle. All patients ment. were receiving a similar weight-maintenance diet of 35 kcal/kg/die, made up of 50% carbohydrate, 20% fat and 30% protein, did not change their lifestyle Metabolic determinations and gave their informed consent to participate in the study which was approved by the Ethics Committee Euglycaemic glucose clamp were performed accordof our Institution. Detailed characteristics of patients ing to De Fronzo et al. 14 Using a fixed insulin are shown in Table 1 .
infusion rate (7.1 pmol/kg × min; Humulin R®, Eli Lilly, Florence, Italy) the pump delivered a variable amount of glucose as 20% solution. Indirect caloriStudy design metry was employed in the basal state (from −60 to The study was designed as a single-blind, random-0 min), and during the last 60 min of the clamp proised placebo-controlled trial. After a 1 week run-in cedure to estimate substrate oxidation. A comperiod, each patient was randomly assigned to plaputerised open-circuit system was used to measure cebo (n = 7) or losartan (n = 9) (50 mg/die; Lortaan ® ; gas exchange through a 25 L polyvinyl-chloride Merck Sharp Dohme-Rome, Italy). Each treatment plastic canopy (Deltatrac, Datex, Milan, Italy). The period lasted 4 weeks. At baseline, and at the end of monitor has a precision of 2.6% for oxygen conplacebo and losartan treatment periods, euglycaemic sumption and 1.0% for carbon dioxide production. hyperinsulinaemic glucose clamps were performed.
All metabolic tests were carried out by investiDuring the treatment periods, placebo and losartan gators unaware of active or placebo treatment groups were given once daily before breakfast. The day of and of arterial BP determination. the clamp, placebo and losartan were given 60 min before starting insulin infusion. Arterial BP was Sampling and analytical methods measured before performing the glucose clamp.
Blood samples were drawn at −20 and 0 min and then at 20 min intervals until the end of the glucose Cardiovascular determinations clamp. Plasma sodium, potassium and calcium levArterial BP was measured according to the criteria els were determined at the end of the run-in period of the Joint National Committee on Detection, Evaluand also after placebo and losartan periods by rouation and Treatment of High Blood Pressure. 13 tine methods. Except for plasma glucose concenBriefly, three BP measurements at 2 min intervals trations which were immediately determined by were taken using a standard mercury sphygmomanusing the glucose oxidase method (Beckman, AutoAnalyzer, Fullerton, USA) blood samples for insulin were collected in ethylene-diaminetetraacetic acid 17 To avoid any interference of body Similarly, basal blood flow (0.223 ± 0.31 vs 0.219 ± 0.031 L/min, P = NS) and per cent insulin mediated weight change on insulin sensitivity, WBGD and substrate oxidation were related to FFM.
increase in blood flow (82 ± 9 vs 84 ± 7%, P = NS) were also not different before placebo and losartan Per cent changes in insulin-mediated stimulation of blood flow and in WBGD were calculated as per administration, respectively. cent increase above baseline values.
All data are expressed as mean ± s.d. Analysis of AT 1 antagonism effects on cardiovascular variance (ANOVA) was used to compare multiple parameters group means. When ANOVA indicated a difference at the 5% level or less, Scheffe's test was employed As seen in Table 2 , SBP and DBP were significantly reduced by losartan administration, while placebo for individual group comparisons. Statistical analyses were made by SOLO software package system did not significantly affect arterial BP. Heart rate was similar in both experimental conditions. (BMDP, Cork, Ireland) on an IBM PC computer.
Results

AT 1 antagonism effects on metabolic parameters
Fasting plasma glucose (5.1 ± 0.4 vs 4.8 ± 0.3 Run-in period mmol/l, P = NS) and insulin (81 ± 7 vs 75 ± 6 pmol/l, Systolic BP (SBP) and DBP, heart rate, body mass P = NS) were not different after placebo and losartan index (BMI) and FFM were stable and unchanged administration, respectively. Basal blood flow (0.224 throughout the run-in period (data not shown). No ± 0.030 vs 0.233 ± 0.031 L/min, P Ͻ 0.05) was sigpatient had intercurrent illness or took drugs that nificantly greater after losartan administration. Durwere known to interfere with glucose metabolism.
ing glucose clamp, plasma glucose concentration As shown in Table 2 , subjects in the placebo and was kept within a narrow range (c.v. = 3.2 ± 0.4 vs losartan groups were of similar age, gender distri-3.1 ± 0.2%, P = NS), and close to basal values (5.1 ± bution, BMI, FFM and cardiovascular parameters. 0.3 vs 5.0 ± 0.5 mmol/L, P = NS) after placebo and losartan administration, respectively. Along with insulin infusion, plasma insulin levels (478 ± 22 vs Baseline parameters 493 ± 19 pmol/l, P = NS) were also not different At baseline body weight (73.5 ± 2.6 vs 75.5 ± 3.1 kg, between placebo and losartan adminstration. In P = NS), BMI (26.2 ± 0.4 vs 25.8 ± 0.3 kg/m 2 , P = NS), metabolic conditions, losartan administration %BF (25 ± 3 vs 26 ± 4%, P = NS), waist/hip ratio against placebo was associated with a significant (0.87 ± 0.03 vs 0.88 ± 0.04, P = NS), SBP (165 ± 4.8 increase in both WBGD and blood flow (Figure 1 ). In vs 163 ± 5.3 mm Hg, P = NS), DBP (97 ± 2.3 vs 99 ± the losartan group, the per cent increase in insulin-3.3 mm Hg, P = NS) and heart rate (74 ± 2.9 vs 75 mediated stimulation of blood flow and in WBGD ± 3.0 beats/min, P = NS) were not different between (r = 0.76, P Ͻ 0.01) were significantly correlated. losartan and placebo groups, respectively. Fasting Evaluation of non-protein nitrogen concentration and steady state plasma glucose and insulin concenin the urine (placebo: 4.2 ± 0.3 mg/ml; losartan: 4.3 tration and basal substrate oxidation were also not ± 0.1 mg/ml, P = NS), and urinary flow (placebo: 2.4 different between the study groups (data not ± 0.4 ml/min; losartan: 2.5 ± 0.4 ml/min, P = NS) shown). Along with insulin infusion, whole body yielded similar estimates of total protein oxidation in both experimental conditions. From these data, (r = 0.07, P = NS) was found.
Waist/hip ratio 0.85 ± 0.04 0.84 ± 0.03 SBP (mm Hg) 163 ± 3.5 147 ± 4.1* DBP (mm Hg) 95 ± 3.2 85 ± 3.2*
Changes in plasma electrolytes levels
Heart rate (beats/min) 73 ± 3.5 76 ± 3. P = NS) concentrations were not significantly differStatistically significant differences between placebo and losartan were: *P Ͻ 0.001.
ent after placebo and losartan administration, Figure 2 Substrate oxidation at fasting and along with insulin infusion after placebo and losartan administration. Statistically significant difference against the same parameter after placebo administration was: *P Ͻ 0.01.
The cardiovascular effects of AT 1 receptor antagonism are well investigated. 18 In particular, it has been demonstrated that losartan, a potent non-peptide AT 1 receptor antagonist, inhibits specifically the binding of angiotensin II to its own receptor 19 and shares an antihypertensive effect with a long duration of action in both inpatients and outpatients. 20 A minimal dose of 50 mg is necessary to sustain the BP lowering effect, while 100 mg provides only minor additional antihypertensive efficacy. The key advantage of AT 1 antagonism against ACE inhibitors is the minimisation or untoward effects as cough, urticaria and angioedema are very rarely encountered. 21 Furthermore, angiotensin II antagonism lacks the bradykinin potentiating action of ACE inhibitors, 10 thus allowing differentiation of the effect due to angiotensin II blockade from that of bradykinin.
Despite a growing body of evidence showing los- little data regarding the effect of AT 1 inhibition on glucose handling have been reported. In particular, it has been demonstrated that losartan administration is associated with an increase of insulin respectively. Insulin infusion was associated with a significant decline (P Ͻ 0.001 in both experimental action. 11 Nevertheless, Moan et al 11 did not measure substrate oxidation and blood flow which might sigconditions) in plasma potassium concentration.
nificantly affect WBGD. As far as blood flow is concerned, previous studies have demonstrated that Adverse effects vasodilatation and constriction may have opposite effects on insulin-mediated glucose uptake. 22 SteinThroughout the study no adverse effects were reported, and no patients dropped out of the study berg et al 23 demonstrated that insulin infusion (120 mU × m 2 × min) and consequent hyperinsulinabecause of excessive or blunted antihypertensive effects. Compliance with drug treatment was 91 ± emia increased blood flow in the leg approximately two-fold as well as insulin-mediated glucose uptake. 0.8%.
The role of leg blood flow on insulin-mediated glucose uptake is also highlighted by studies in insulinDiscussion resistant states. Obese insulin-resistant patients exhibit impaired metacoline-induced vasodilatation Our study shows that AT 1 antagonism improves insulin action through an improvement in nonunder basal and insulin-stimulated conditions, 2 a haemodynamic phenomena paralleling the impairoxidative NOGM and blood flow. 
